PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34736968-5	2021	Oral administration of niclosamide reduced TAC-induced increase of serum IL-6 in heart failure mice.	Niclosamide	23-34	interleukin 6	Mus musculus	73-77	
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	75-89	
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	91-95	
34736968-8	2021	In cultured primary cardiomyocytes and cardiac fibroblasts, niclosamide (more than 0.1 muM) suppressed IL-6- and phenylephrine-induced cardiomyocyte hypertrophy, and inhibited collagen secretion from cardiac fibroblasts.	Niclosamide	60-71	interleukin 6	Mus musculus	103-107	
34736968-9	2021	In conclusion, niclosamide attenuates heart failure in mice and the underlying mechanisms include enhancing mitochondrial respiration of cardiomyocytes, inhibiting collagen secretion from cardiac fibroblasts, and reducing the elevated serum inflammatory mediator IL-6.	Niclosamide	15-26	interleukin 6	Mus musculus	263-267	
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	interleukin 6	Mus musculus	91-95	
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Niclosamide	0-11	interleukin 6	Mus musculus	61-64